These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 19929593

  • 1. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR, Alva G, Meng X, Olin JT.
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [Abstract] [Full Text] [Related]

  • 2. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
    Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, Lee JH, Expect Study Group.
    Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K, Baier M, Tracik F, Kühn F, Preuss UW, Kurz A.
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [Abstract] [Full Text] [Related]

  • 8. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
    Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS.
    Int J Clin Pract; 2002 Mar; 56(6):441-6. PubMed ID: 12166542
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D.
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [Abstract] [Full Text] [Related]

  • 10. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [Abstract] [Full Text] [Related]

  • 11. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
    Sadowsky CH, Farlow MR, Meng X, Olin JT.
    Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
    Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J.
    Dement Geriatr Cogn Disord; 2012 Jan; 33(2-3):164-73. PubMed ID: 22572767
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 14. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
    Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I.
    Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
    Grossberg GT, Olin JT, Somogyi M, Meng X.
    Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
    Schmidt R, Alf C, Bancher C, Benke T, Berek K, Dal-Bianco P, Führwürth G, Imarhiagbe D, Jagsch C, Lechner A, Rainer M, Reisecker F, Rotaru J, Uranüs M, Walter A, Winkler A, Wuschitz A.
    Neuropsychiatr; 2009 Apr; 23(1):58-63. PubMed ID: 19272293
    [Abstract] [Full Text] [Related]

  • 19. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
    Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X.
    Dement Geriatr Cogn Disord; 2010 Apr; 29(5):406-12. PubMed ID: 20502014
    [Abstract] [Full Text] [Related]

  • 20. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
    Lee JH, Sevigny J.
    Alzheimer Dis Assoc Disord; 2011 Apr; 25(1):58-62. PubMed ID: 20975519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.